Wednesday, 28 September, 2022
HomeHealthJohnson & Johnson seeks nod to conduct vaccine trails for 12-17 age...

Johnson & Johnson seeks nod to conduct vaccine trails for 12-17 age group in India

Earlier in August, the US pharma giant Johnson & Johnson was given emergency use approval in India for its single-dose Covid-19 vaccine.

Text Size:

New Delhi: US pharma giant Johnson & Johnson has moved an application before the Central Drugs Standard Control Organisation (CDSCO) in India, seeking permission to conduct clinical trials of its single-dose Janssen vaccine against COVID-19 on adolescents (children of age group 12-17 years).

Earlier in August, Johnson & Johnson’s was given emergency use approval in India for its single-dose COVID-19 vaccine. A statement by Johnson & Johnson read, “On August 17, 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson COVID-19 vaccine in India in adolescents aged 12 – 17 years.”

“To ultimately achieve herd immunity, it is imperative that COVID-19 vaccine clinical trials continue to move forward in this population, and we remain deeply committed to the critical work needed to make our COVID-19 vaccine equitably accessible for all age groups,” the company’s spokesperson said.

The five vaccines which were granted emergency use authorisation in India are Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, Moderna and Now Johnson & Johnson (J&J).


Also read: Johnson & Johnson’s Covid vaccine gets emergency use approval in India


 

Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular

×